Immunotherapy tested for Tough-to-Treat ovarian cancer
NCT ID NCT05737199
Summary
This study is testing the immunotherapy drug pembrolizumab for women with advanced or recurrent ovarian squamous cell carcinoma that cannot be removed by surgery. The goal is to see if the drug can shrink tumors and help patients live longer. The trial will enroll 21 participants who will receive the drug for up to two years while researchers monitor their response and any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Niigata University Medical & Dental Hosptal
Niigata, Niigata, 951-8510, Japan
Conditions
Explore the condition pages connected to this study.